EARN25

Amarin Stock Rallies as Vascepa Earns ADA Nod

The American Diabetes Association recommended Amarin's omega-3 triglyceride treatment

Managing Editor
Mar 28, 2019 at 10:08 AM
facebook X logo linkedin


Amarin Corporation (NASDAQ:AMRN) stock is up 4.5%% to trade at $18.75, after the American Diabetes Association (ADA) recommended Vascepa, Amarin's fish oil-based triglyceride treatment, for patients with diabetes and certain types of heart disease. Jefferies called the decision an "incremental positive," while Cantor Fitzgerald reiterated its "overweight" rating and $35 price target. 

That $35 price target represents territory AMRN hasn't approached since 2007. After flashing a buy signal earlier this month, Amarin stock is now on track for its third straight daily win after finding support at its 80-day moving average. Year-over-year, the shares boast a 523% gain, thanks mostly to a huge bull gap back in late September following breakthrough Vascepa data.

In the options pits, calls have been heavily preferred over puts on AMRN lately. Data from the International Securities Exchange (ISE), Chicago Board Options Exchange (CBOE), and NASDAQ OMX PHLX (PHLX) shows speculative players have bought to open 23,461 calls in the last 10 sessions, compared to just 3,564 puts. However, given that short interest on AMRN has increased by 16.3% in the two most recent reporting periods, some of this call-buying activity could be the result of bearish bettors hedging against any upside risk.

Regardless of the motive, AMRN option premiums are attractively priced at the moment. Specifically, AMRN's Schaeffer's Volatility Index (SVI) of 82% ranks in the 7th percentile of its annual range. In other words, front-month options are pricing in unusually low volatility expectations.
 

You Don’t Need 25 Alerts -- You Need ONE You Can Trust!

That’s the idea behind Trade of the Week, Schaeffer’s newest trade alert.

Every Monday morning before the opening bell, you’ll receive a single, expertly researched trade recommendation -- built from the same proprietary research we’ve been using for over four decades.

It’s not just a signal.

It’s a plan designed for traders who are tired of jumping from alert to alert without ever finding their edge.

No juggling alerts. No switching directions mid-week. Just one clear, expertly researched trade idea -- delivered before the market even opens.

👉 JOIN RIGHT NOW FOR JUST $1 TO GET THE NEXT TRADE!